HCA Healthcare Inc. reported $1.81 million in Q1 2026 lobbying expenditures on healthcare legislation, along with $28.3 million in insider stock sales. Analyst ratings remain positive with a median price target of $550.5.

NodeGuardian

2026-04-21 05:56:52

Abstract generation in progress

HCA Healthcare Inc. recently disclosed $1,810,000 in lobbying expenditures for Q1 2026, focusing on healthcare legislation. The article also details significant insider stock sales ($28.3 million) and institutional investor activity, with some major firms decreasing positions while others increased. Analyst ratings for HCA are predominantly positive, with a median price target of $550.5.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

Reward
like
Comment
Repost
Share

Comment

Add a comment

No comments

Trending Topics
View More
#
GatePreIPOsLaunchesWithSpaceX
297.26K Popularity
#
Gate13thAnniversaryLive
868.1K Popularity
#
BitcoinBouncesBack
171.36K Popularity
#
USIranTalksProgress
877.82K Popularity
#
HKUnveilsNewCryptoRules
274.26K Popularity

Sitemap

Lobbying Update: $1,810,000 of HCA HEALTHCARE INC. lobbying was just disclosed

Trending Topics

GatePreIPOsLaunchesWithSpaceX

Gate13thAnniversaryLive

BitcoinBouncesBack

USIranTalksProgress

HKUnveilsNewCryptoRules

Pin